Trade Names:Bismatrol- Tablets, chewable 262 mg
Trade Names:Bismatrol Extra Strength- Liquid 524 mg/15 mL
Trade Names:Pepto-Bismol Maximum Strength- Liquid 524 mg/15 mL
Trade Names:Pepto-Bismol- Liquid 262 mg/15 mL- Tablets, chewable 262 mg- Caplets 262 mg
Trade Names:Pink Bismuth- Liquid 130 mg/15 mL- Liquid 262 mg/ 15 mLPink Bismuth (Canada)
Produces antisecretory and antimicrobial effects; may have anti-inflammatory effect.
In the GI tract, bismuth subsalicylate undergoes chemical dissociation to yield bismuth and salicylate. Bismuth absorption is negligible, and plasma levels of the salicylate are similar to levels achieved after a comparable dose of aspirin.
Chemical dissociation in the GI tract.
Greater than 90% of salicylate is recovered in urine.
Treatment of indigestion without causing constipation, nausea, abdominal cramps; control of diarrhea, including traveler's diarrhea.
Treatment of recurrent ulcers, chronic infantile diarrhea, gastroenteritis associated with Norwalk virus; prevention of traveler's diarrhea.
Viral illness such as chickenpox or influenza in patients younger than 18 yr of age.
PO 2 tablets (262 mg each) or 30 mL suspension every 30 to 60 min as needed (max, 8 doses/day).Children 9 to 12 yr of age
PO 1 tablet or 15 mL suspension every 30 to 60 min as needed (max, 8 doses/day).Children 6 to 9 yr of age
PO 2/ 3 tablet or 10 mL suspension every 30 to 60 min as needed (max, 8 doses/day).Children 3 to 6 yr of age
PO 1/ 3 tablet or 5 mL suspension every 30 to 60 min as needed (max, 8 doses/day).Children younger than 3 yr of age
Consult health care provider.
Store at room temperature. Protect from light.
May cause salicylate toxicity.Corticosteroids
May decrease effectiveness.Insulin
Drug may increase glucose-lowering effect of insulin.Methotrexate
Drug may increase effects and toxicity of methotrexate.Spironolactone
Drug may interfere with diuretic effect.Sulfinpyrazone
Drug may interfere with uricosuric effect.Tetracyclines
Bismuth subsalicylate may reduce GI absorption of tetracyclines and diminish their effectiveness.Valproic acid
Drug may increase free fraction of valproic acid, leading to toxicity.
Bismuth subsalicylate is radiopaque and may interfere with radiologic examination of GI tract.
Tinnitus; discoloration of tongue.
Discoloration of stools; impaction.
Category C .
Excreted in breast milk.
May cause impaction.
May cause impaction.
Ringing in ears, respiratory alkalosis, nausea, vomiting, hypokalemia, neurologic abnormalities (eg, disorientation, seizures), dehydration, hyperthermia, unusual bleeding or bruising.
Copyright © 2009 Wolters Kluwer Health.